Study guide
6.1 Dosage Forms, Drug Delivery, and Dissolution
NABP FPGEE Foreign Pharmacy Graduate Equivalency Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the FPGEE 1.2 How to Use This Study Guide
2 Chapter 2: Foundational Biomedical Sciences I
2.1 Anatomy 2.2 Physiology 2.3 Biochemistry
3 Chapter 3: Foundational Biomedical Sciences II
3.1 Medical Microbiology 3.2 Immunology 3.3 Pathophysiological Bases of Diseases
4 Chapter 4: Pharmaceutical Calculations, Compounding, and Medicinal Chemistry
4.1 Pharmaceutical Calculations 4.2 Extemporaneous Compounding 4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways 4.4 Structure-Activity Relationships and Drug-Receptor Interactions
5 Chapter 5: Pharmacology and Toxicology
5.1 Pharmacodynamics and Dose-Response 5.2 Mechanisms of Action of Drugs and Biologics 5.3 Adverse Effects, Side Effects, and Drug Interactions 5.4 Toxicology and Antidotes
6 Chapter 6: Pharmaceutics, Biopharmaceutics, and Pharmacokinetics
6.1 Dosage Forms, Drug Delivery, and Dissolution 6.2 Stability, Shelf-Life, and Manufacturing 6.3 ADME Rates, Half-Lives, and Compartment Models 6.4 Bioavailability, Bioequivalence, Biosimilars, and Pharmacogenomics
7 Chapter 7: Pharmacy Law, Ethics, and Health Care Systems
7.1 Pharmacy Law and Regulations 7.2 Ethics and Regulatory/Oversight Organizations 7.3 US Health Care Systems 7.4 Pharmacoeconomics
8 Chapter 8: Public Health, Practice Management, and Biostatistics
8.1 Pharmacoepidemiology, Population-Based Care, and Public Health 8.2 Practice Management 8.3 Continuous Quality Improvement, Risk Management, and Inventory Control 8.4 Biostatistics and Research Methods
9 Chapter 9: Professional Communication and Behavioral Aspects
9.1 Professional Communication 9.2 Social and Behavioral Aspects of Practice
10 Chapter 10: Clinical Sciences I — Pathophysiology and Patient Assessment
10.1 Clinical Pathophysiology: Cardiovascular and Endocrine 10.2 Clinical Pathophysiology: Respiratory, GI, Renal, and Other Systems 10.3 Patient Data Collection 10.4 Patient Data Assessment 10.5 Patient-Care Decision Making, Therapy Recommendations, and Education
11 Chapter 11: Clinical Sciences II — Patient Safety, Prevention, and Personalized Care
11.1 Patient Safety: Drug Interactions and Toxicity 11.2 Drug-Induced Disease and Drug Use Disorders 11.3 Disease Prevention 11.4 Personalized Medicine
12 Chapter 12: Clinical Sciences III — Evidence-Based Practice
12.1 Practice Guidelines and Drug Information 12.2 Clinical Trial Evaluation and Information Source Reliability
13 Chapter 13: Clinical Sciences IV — Self-Care and Natural Products
13.1 Self-Care and Natural Products
6.1 Dosage Forms, Drug Delivery, and Dissolution
Key Takeaways Explain This Topic AI
Dosage forms are classified by physical state (solid, liquid, semisolid, gaseous, injectable) and by release profile (immediate, sustained, controlled, extended, delayed).
The Noyes-Whitney equation, dC/dt = (D·S/h)(Cs - C), shows that dissolution rate rises with solubility, surface area, and diffusion coefficient, and falls with boundary-layer thickness.
USP Apparatus 1 (basket) and Apparatus 2 (paddle) are the standard compendial dissolution testers; sink conditions are maintained so that dissolved drug stays below ~20% of saturation.
The Biopharmaceutics Classification System (BCS) sorts drugs into four classes by solubility and permeability, predicting oral absorption and waiver eligibility.
Advanced delivery systems (transdermal patches, implants, liposomes, nanoparticles, depot injections) modify release kinetics, target sites, and protect labile molecules.
Last updated: July 2026
Dosage Form Classification
A dosage form is the physical form in which a drug is administered. Classification by physical state organizes every product a pharmacist dispenses:
Solid — tablets, capsules, granules, powders, lozenges. Solids are stable, dose-accurate, and convenient. Tablets dominate because of low cost, precision, and patient acceptance.
Liquid — solutions, suspensions, emulsions, syrups, elixirs, tinctures. Liquids are easier to swallow and faster to absorb (no disintegration step) but less stable, bulkier, and harder to dose precisely.
Semisolid — ointments, creams, gels, pastes, suppositories. Used topically, rectally, vaginally, or transdermally for local or systemic effect.
Gaseous/aerosol — metered-dose inhalers (MDIs), dry-powder inhalers (DPIs), nebulized solutions. Deliver drug directly to the respiratory tree for asthma, COPD, and some infections.
Injectable — solutions, suspensions, or emulsions given by IV, IM, SC, intrathecal, or intradermal routes. Bypass absorption barriers; require sterility, pyrogen control, and isotonicity.
Drug Delivery Systems and Release Profiles
Release kinetics define when and how fast drug appears in solution at the absorption site:
Immediate release (IR) — disintegrates and dissolves promptly; onset is rapid but duration is short (e.g., immediate-release metoprolol).
Sustained release (SR) and Controlled release (CR) — slow the release to maintain plasma levels within the therapeutic window over a prolonged period, reducing dosing frequency and peak-related side effects.
Extended release (ER/XR) — a regulatory term encompassing SR and CR products; FDA labels use ER.
Delayed release (DR) — release occurs at a time or site distinct from administration; enteric-coated aspirin and delayed-release proton-pump inhibitors bypass the stomach to protect the drug or the gastric mucosa.
Disintegration and Dissolution
A solid oral dosage form must disintegrate into primary particles before drug can dissolve . For poorly soluble drugs, dissolution is the rate-limiting step in absorption.
The Noyes-Whitney equation describes dissolution kinetics:
dC/dt = (D · S / h) · (Cs − C)
where D is the diffusion coefficient, S the effective surface area, h the stagnant boundary-layer thickness, Cs the saturation solubility, and C the bulk concentration. Formulators raise dissolution rate by micronization (increasing S), salt formation (raising Cs), amorphous solid dispersions (raising apparent Cs), and surfactants (wetting particles and lowering h). Polymer polymorphism also matters: the metastable polymorph dissolves faster but may convert to the stable form on storage.
USP dissolution apparatus : Apparatus 1 (basket, 50-120 rpm) suits capsules and floating dosage forms; Apparatus 2 (paddle, 50-200 rpm) is the most common for tablets. Media are typically 500-900 mL of simulated gastric or intestinal fluid at 37 °C, with sampling at defined intervals to plot a dissolution profile. Sink conditions — keeping C below about 20% of Cs — prevent backward driving of dissolution and let the data reflect intrinsic drug release.
Physicochemical Properties of Drugs and Excipients
A tablet is not drug alone; excipients make it manufacturable, stable, and bioavailable:
Fillers (diluents) — lactose, microcrystalline cellulose; provide bulk.
Binders — povidone, starch paste; hold granules together.
Disintegrants — croscarmellose, sodium starch glycolate, crospovidone; swell or wick water to break the tablet apart.
Lububricants — magnesium stearate, stearic acid; reduce friction and sticking but, in excess, hydrophobic coatings can slow dissolution.
Glidants — colloidal silicon dioxide; improve powder flow.
Preservatives — benzalkonium chloride, parabens, sodium benzoate; protect multi-dose liquids from microbial growth.
Surfactants — polysorbates, sodium lauryl sulfate; wet particles and, above the critical micelle concentration, solubilize lipophilic drugs.
Buffers and tonicity agents — citrate, phosphate, sodium chloride; maintain pH and osmolality in parenterals and ophthalmics.
Biopharmaceutics Classification System (BCS)
The BCS predicts oral absorption from two properties: solubility (drug dissolves completely in 250 mL across the physiological pH range) and permeability (>90% absorbed across the intestine). FDA BCS-based biowaivers allow certain Class I and Class III generics to skip in vivo bioequivalence studies.
- Class Solubility Permeability Examples Absorption limiter
- I High High Metoprolol, propranolol, enalapril Gastric emptying
- II Low High Ketoprofen, naproxen, carbamazepine, itraconazole Dissolution
- III High Low Atenolol, metformin, cimetidine, ranitidine Permeability
- IV Low Low Furosemide, hydrochlorothiazide, paclitaxel Both; high variability
Class II drugs benefit most from formulation strategies (micronization, amorphous dispersions, lipid systems) that boost apparent solubility. Class IV drugs often require enabling formulations or alternative routes.
Advanced Drug Delivery Technologies
Transdermal patches — drug embedded in a polymer matrix or reservoir with a rate-controlling membrane; bypasses gut and liver first-pass, but only small lipophilic molecules (estradiol, fentanyl, nicotine, scopolamine) permeate intact skin.
Implants and depots — subcutaneous or intramuscular depots (depot medroxyprogesterone, haloperidol decanoate) and nondegradable implants (etonogestrel rod, leuprolide polymeric implant) deliver drug over weeks to years.
Liposomes — phospholipid vesicles entrap drug, reduce toxicity (liposomal doxorubicin, amphotericin B liposome), and exploit leaky tumor vasculature via the enhanced permeability and retention (EPR) effect.
Nanoparticles — polymeric or lipid nanoparticles improve solubility (paclitaxel albumin nanoparticles) and enable targeted delivery.
Prodrugs and antibody-drug conjugates — chemical linkage masks a poorly permeable or unstable drug; enzymatic or linker cleavage releases active species at the target.